

**SYNTHESIS OF NEW SULFUR-LINKED THIENOTRIAZOLOPYRIMIDINE
DERIVATIVES CONTAINING TRIAZOLOTHIADIAZOLE MOIETY**

Jina Whang and Yang-Heon Song*

*Department of Chemistry, Mokwon University, Daejeon 302-729, South Korea
E-mail: yhsong@mokwon.ac.kr*

Abstract

A series of new sulfur-linked heterocyclic compounds **11** were synthesized by the successive reactions of thieno[1,2,4]triazolo[4,3-*c*]pyrimidine-3-thione with α -bromophenylacetic acid derivatives and 4-amino-4*H*-[1,2,4]triazole-3,5-dithiol.

Keywords: thienotriazolopyrimidine, triazolothiadiazole, cyclization, phosphorus oxychloride

Introduction

Thienotriazolopyrimidine derivatives have attracted much attention and are of great interest as potential therapeutic agents. For instance, thienotriazolopyrimidine **1** as shown in Figure 1 and its analog have been recently explored for inhibitor of Shiga toxin trafficking and adenosine A₁/A_{2A} or A_{2A}/A₃ receptor antagonists, respectively.^{1,2} We have previously designed and synthesized thienotriazolopyrimidine derivatives **2** with promising biological activity using iodobenzene diacetate.³

Moreover, sulfur-containing 1,2,4-triazoles (3-thio-1,2,4-triazoles) were also reported to possess an impressive array of biological activities such as antibacterial, antifungal, analgesic, somatostatin sst₂/sst₅ agonist and carbonic anhydrase inhibitor.⁴⁻⁷ Particularly, sulfur-linked diheterocyclic compounds containing triazolopyrimidine or triazole such as **3** and **4** were investigated for antifungal agent and plant growth regulator, respectively.^{8,9} We also have recently reported the synthesis of diheterocyclic compound **5** and its analogs.¹⁰

In the other hand, 1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazole derivatives obtained by fusing 1,2,4-triazole and 1,3,4-thiadiazole ring together, have been reported to possess antibacterial, antifungal, anti-inflammatory, analgesic effects and anticancer activity.¹¹⁻¹³ For example, compound **6** and other 1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazole derivatives were reported to have anti-inflammatory and antimicrobial activities, respectively.¹⁴⁻¹⁶

Therefore, we devised the introduction of a 1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazole moiety to the thieno[1,2,4]triazolo[4,3-*c*]pyrimidine ring by sulfur to produce novel diheterocyclic systems using the concept of molecular hybridization.¹⁷

As a continuation of our synthetic works on heterocyclic compounds related to thienopyrimidines and thienopyridine with biological interest,¹⁸ we wish to report herein the synthesis of new sulfur-linked thienotriazolopyrimidines **11a-e** containing a 1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazole, which are structurally related to **5** and **6** in the hope of obtaining compounds of diverse biological activities.





Figure 1. Compounds 1-6.

Result and Discussion


As reported in a previous communication,¹⁰ a key intermediate thieno[3,2-*e*][1,2,4] triazolo[4,3-*c*]pyrimidine-3(2*H*)-thione (**7**) can be prepared in a few step sequence using 2-aminothiophene-3-carbonitrile as a starting material. The compounds of phenyl-(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)-acetic acid (**9**) and its derivatives were obtained in good yield by treatment of **7** with α -bromophenylacetic acid derivatives **8** containing sodium acetate (Scheme 1). The structure of these compounds was evident from their elemental analysis, mass spectra, ¹H NMR and IR spectra. The disappearance of characteristic peaks at 1200 (weak) and 3190 cm⁻¹ for the C=S and NH groups in IR spectrum and the secondary amino signal near at δ 14.0 in ¹H NMR spectrum indicated the thione **7** was converted into the corresponding cyclic triazole products **9a-e**. For instance, the ¹H NMR spectrum of **9a** showed two doublets at δ 8.02-7.73 for thiophene protons, multiplet signals at δ 7.58-7.14 for aromatic protons and two singlets at δ 9.49 and 5.44 for pyrimidine and benzylic proton, respectively. The mass spectral data of **9a** showed a molecular ion peak at *m/z* 342 (12%), and also showed ions at *m/z* 324 (22%) and 298 (78%) which could be attributed to the loss of H₂O and CO₂, respectively, from the molecular ion.



a: R = H; b: R = 2-Cl; c: R = 3-Cl; d: R = 4-Cl; e: R = 4-Br

Scheme 1

6-[Phenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)-methyl]-2*H*-[1,2,4] triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione and its derivatives (**11a-e**) were prepared from the reaction of **9a-e** with 4-amino-4*H*-[1,2,4]triazole-3,5-dithiol (**10**)¹⁹ using phosphorus oxychloride as the cyclizing agent (Scheme 2).^{15,20}



a: R = H; b: R = 2-Cl; c: R = 3-Cl; d: R = 4-Cl; e: R = 4-Br

Scheme 2

The structure of these compounds was also characterized from their elemental analysis, mass spectra, ¹H NMR and IR spectra. For example, the characteristic bands at 1210 and 3190 cm⁻¹ for the C=S and NH stretching vibrations in IR spectrum of **11b** were identified, like compound **7** having the same functional groups. The ¹H NMR spectrum of **11b** showed two doublets at δ 8.05 and 7.77 for thiophene protons, three multiplets at δ 7.59, 7.51 and 7.38-7.35 for aromatic protons and two singlets at δ 9.59 and 6.07 for pyrimidine and benzylic proton, respectively. The mass spectral data of **11b** showed a molecular ion peak at m/z 487 (1.2%), and also showed ions at m/z 332 (100%), 297 (54%), 155 (42%) and 135 (62%) which could be attributed to the loss of 1,2,4-triazolo[3,4-*b*][1,3,4]thiadiazole moiety and followed by next fragmentation, respectively, from the molecular ion. The ions at 208, 177 were fragments obtained from cleavage of sulfide bond of **11b**.

In conclusion, we have reported the synthesis of new sulfur-linked heterocyclic compounds **11a-e** with potential biological activities.

Experimental section

Melting points were determined in capillary tubes on Büchi apparatus and are uncorrected. Each compound of the reactions was checked on thin-layer chromatography of Merck Kieselgel 60F₂₅₄ and purified by column chromatography Merck silica gel (70-230 mesh). The ¹H NMR spectra were recorded on Bruker DRX-300 FT NMR spectrometer (300 MHz) with Me₄Si as internal standard and chemical shifts are given in ppm (δ). IR spectra were recorded using an EXCALIBUR FTS-3000 FT IR spectrophotometer. Electron ionization mass spectra were recorded on a HP 59580 B spectrometer. Elemental analyses were performed on a Carlo Erba 1106 elemental analyzer.

General procedure for the preparation of 9a-e. To a solution of thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidine-3(2*H*)-thione (**7**) (1.2 mmol) in ethanol (20 mL) anhydrous sodium acetate (2 mmol) was added with stirring at room temperature. After 5 min, α-bromophenylacetic acid derivatives **8** (1.2 mmol) was added slowly in small portions and the resulting solution was heated at reflux for 6 hours. After cooling, the solid products formed were filtered, washed with

water and purified with silica gel column chromatography eluting with 50:50 v/v CHCl₃/MeOH mixture .

Phenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)acetic acid (9a).

The compound was obtained in 65% yield, mp 206-208°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.45 (s, 1H, H-5, pyrimidine), 8.02 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.73 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.58 (m, 2H, Ar), 7.37-7.14 (m, 3H, Ar), 5.44 (s, 1H, benzyl), ms: (m/z) 342 (M⁺), 324, 298, 265, 208, 135, 121. *Anal.* Calcd. for C₁₅H₁₀N₄O₂S₂: C, 52.62; H, 2.94; N, 16.36. Found: C, 52.49; H, 2.82; N, 16.42.

2-Chlorophenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)acetic acid (9b).

The compound was obtained in 80% yield, mp 222-223°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.54 (s, 1H, H-5, pyrimidine), 8.04 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.75 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.65 (d, 1H, Ar), 7.48 (d, 1H, Ar), 7.35-7.27 (m, 2H, Ar), 6.01 (s, 1H, benzyl), ms: (m/z) 376 (M⁺), 331, 297, 264, 208, 135, 77. *Anal.* Calcd. for C₁₅H₁₉ClN₄O₂S₂: C, 47.81; H, 2.41; N, 14.87. Found: C, 47.89; H, 2.48; N, 14.77.

3-Chlorophenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)acetic acid (9c).

The compound was obtained in 72% yield, mp 233-235°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.49 (s, 1H, H-5, pyrimidine), 8.02 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.73 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.62 (s, 1H, Ar), 7.52 (m, 1H, Ar), 7.28-7.21 (m, 2H, Ar), 5.40 (s, 1H, benzyl), ms: (m/z) 376 (M⁺), 332, 299, 264, 208, 177, 155, 135, 77. *Anal.* Calcd. for C₁₅H₁₉ClN₄O₂S₂: C, 47.81; H, 2.41; N, 14.87. Found: C, 47.74; H, 2.35; N, 14.80.

4-Chlorophenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)acetic acid (9d).

The compound was obtained in 70% yield, mp 214-216°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.56 (s, 1H, H-5, pyrimidine), 8.04 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.75 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.60 (d, 2H, Ar), 7.41 (d, 2H, Ar), 5.72 (s, 1H, benzyl), ms: (m/z) 376 (M⁺), 358, 332, 299, 155, 135, 77. *Anal.* Calcd. for C₁₅H₁₉ClN₄O₂S₂: C, 47.81; H, 2.41; N, 14.87. Found: C, 47.75; H, 2.44; N, 14.95.

4-Bromophenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)acetic acid (9e).

The compound was obtained in 63% yield, mp 266-267°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.58 (s, 1H, H-5, pyrimidine), 8.06 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.77 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.58 (d, 2H, Ar), 7.52 (d, 2H, Ar), 5.70 (s, 1H, benzyl), ms: (m/z) 421 (M⁺), 403, 377, 344, 134, 77. *Anal.* Calcd. for C₁₅H₁₉BrN₄O₂S₂: C, 42.76; H, 2.15; N, 13.30. Found: C, 42.70; H, 2.08; N, 13.38.

General procedure for the preparation of 11a-e. A mixture of 4-amino-4*H*-1,2,4-triazole-3,5-dithiol (**10**) (6.7 mmol) and the appropriate carboxylic acid **9a-e** (6.7 mmol) in phosphorus oxychloride (10 mL) was heated at reflux for 10 hours. The excess phosphorus oxychloride was removed under reduced pressure, and the residue was diluted with ice-water mixture. The precipitated solid was filtered, washed several times with water, dried at room temperature, and recrystallized from DMF.

6-[Phenyl(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)methyl]-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione (11a).

The compound was obtained in 55% yield, mp 157-159°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.62 (s, 1H, H-5, pyrimidine), 8.09 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.82 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.60 (d, 2H, Ar), 7.37-7.25 (m, 3H, Ar), 5.78 (s, 1H, benzyl), ms: (m/z) 454 (M⁺), 297, 177, 135, 77. *Anal.* Calcd. for C₁₇H₁₀N₈S₄: C, 44.92; H, 2.22; N, 24.65. Found: C, 45.05; H, 2.11; N, 24.50.

6-[(2-Chlorophenyl)(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)methyl]-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione (11b).

The compound was obtained in 62% yield, mp 160-162°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.59 (s, 1H, H-5, pyrimidine), 8.05 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.77 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.59 (m, 1H, Ar), 7.51 (m, 1H, Ar), 7.38-7.35 (m, 2H, Ar), 6.07 (s, 1H, benzyl), ms: (m/z) 487 (M⁺), 341, 332, 297, 264, 208, 177, 155, 135, 77. *Anal.* Calcd. for C₁₇H₉ClN₈S₄: C, 41.75; H, 1.86; N, 22.91. Found: C, 41.67; H, 1.90; N, 22.82.

6-[(3-Chlorophenyl)(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)methyl]-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione (11c).

The compound was obtained in 50% yield, mp 184-186°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.58 (s, 1H, H-5, pyrimidine), 8.05 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.75 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.64 (s, 1H, Ar), 7.53 (m, 1H, Ar), 7.29-7.23 (m, 2H, Ar), 6.00 (s, 1H, benzyl), ms: (m/z) 489 (M⁺), 332, 297, 208, 155, 135, 77. *Anal.* Calcd. for C₁₇H₉ClN₈S₄: C, 41.75; H, 1.86; N, 22.91. Found: C, 41.69; H, 1.80; N, 22.84.

6-[(4-Chlorophenyl)(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)methyl]-2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione (11d).

The compound was obtained in 66% yield, mp 164-166°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.59 (s, 1H, H-5, pyrimidine), 8.05 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.77 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.58 (d, 2H, Ar), 7.39 (d, 2H, Ar), 5.75 (s, 1H, benzyl), ms: (m/z) 489 (M⁺), 332, 297, 177, 155, 135. *Anal.* Calcd. for C₁₇H₉ClN₈S₄: C, 41.75; H, 1.86; N, 22.91. Found: C, 41.80; H, 1.78; N, 22.95.

6-[(4-Bromophenyl)(thieno[3,2-*e*][1,2,4]triazolo[4,3-*c*]pyrimidin-3-ylthio)-methyl]2*H*-[1,2,4]triazolo[3,4-*b*][1,3,4]thiadiazole-3-thione (11e).

The compound was obtained in 68% yield, mp 199-201°C; ¹H NMR (dimethyl sulfoxide-*d*₆): 9.61 (s, 1H, H-5, pyrimidine), 8.06 (d, *J* = 5.8 Hz, 1H, H-8, thiophene), 7.78 (d, *J* = 5.8 Hz, 1H, H-9, thiophene), 7.59 (d, 2H, Ar), 7.53 (d, 2H, Ar), 5.73 (s, 1H, benzyl), ms: (m/z) 533 (M⁺), 375, 177, 135. *Anal.* Calcd. for C₁₇H₉BrN₈S₄: C, 38.27; H, 1.70; N, 21.00. Found: C, 38.40; H, 1.62; N, 21.12.

Acknowledgement

This work was supported by the Korea Research Foundation (project number 2010-0021038).

References

1. L. J. Guetzoyan, R. A. Spooner, J. M. Lord, L. M. Roberts, and G. J. Clarkson, *Eur. J. Med.*

- Chem.*, 2010, **45**, 275.
2. (a) M. R. Prasad, A. R. Rao, P. S. Rao, K. S. Rajan, S. Meena, and K. Madhavi, *Eur. J. Med. Chem.*, 2008, **43**, 614. (b) T. Nagamatsu, S. Ahmed, A. M. L. Hossion, and S. Ohno, *Heterocycles*, 2007, **73**, 777.
 3. B. S. Jo, H. Y. Son, and Y.-H. Song, *Heterocycles*, 2008, **75**, 3091.
 4. K. Colanceska-Ragenovic, V. Dimova, V. Kakurinov, D. G. Molnar, and A. Buzarovska, *Molecules*, 2001, **6**, 815.
 5. A. Siwek, M. Wujec, M. Dobosz, E. Jagiełło-Wójtowicz, A. Chodkowska, A. Kleinrok, and P. Paneth, *Cent. Eur. J. Chem.*, 2008, **6**, 47.
 6. M.-O. Contour-Galcéra, A. Sidhu, P. Plas, and P. Roubert, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 3555.
 7. G. L. Almajan, A. Innocenti, L. Puccetti, G. Manole, S. Barbuceanu, I. Saramet, A. Scozzafava, and C. T. Supuran, *Bioorg. Med. Chem. Lett.*, 2005, **15**, 2347.
 8. Q. Chen, X.-L. Zhu, L.-L. Jiang, Z.-M. Liu, and G.-F. Yang, *Eur. J. Med. Chem.*, 2008, **43**, 595.
 9. K. A. Eliazyan, L. V. Shahbazyan, V. A. Pivazyan, and A. P. Yengoyan, *J. Heterocycl. Chem.*, 2011, **48**, 188.
 10. Y.-H. Song and H. Y. Son, *J. Heterocycl. Chem.*, 2010, **47**, 1183.
 11. A.-M. M. E. Omar and O. M. AboulWafa, *J. Heterocycl. Chem.*, 1986, **23**, 1339.
 12. Z. Y. Zhang and X. W. Sun, *Heterocycles*, 1998, **48**, 561.
 13. K. S. Bhat, D. J. Prasad, B. Poojary, and B. S. Holla, *Phosphorus Sulfur and Silicon*, 2004, **179**, 1595.
 14. M. Amir, H. Kumar, and S. A. Javed, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 4504.
 15. N. S. A. M. Khalil, *Nucleosides Nucleotides Nucleic Acids*, 2007, **26**, 347.
 16. N. S. A. M. Khalil, *Eur. J. Med. Chem.*, 2007, **42**, 1193.
 17. C. Viegas-Junior, A. Danuello, V. S. Bolzani, E. J. Barreiro, and C. A. M. Fraga, *Curr. Med. Chem.*, 2007, **14**, 1829.
 18. (a) Y.-H. Song and H. Y. Son, *J. Heterocycl. Chem.*, 2011, **48**, 597. (b) H. M. Lee and Y.-H. Song, *Bull. Korean Chem. Soc.*, 2010, **31**, 2242 (c) B. S. Jo and Y.-H. Song, *Syn. Commun.*, 2009, **39**, 4407. (d) Y.-H. Song and B. S. Jo, *J. Heterocycl. Chem.*, 2009, **46**, 1132. (e) Y.-H. Song, B. S. Jo, and H. M. Lee, *Heterocycl. Commun.*, 2009, **15**, 203. (f) Y.-H. Song and J. Seo, *J. Heterocycl. Chem.*, 2007, **44**, 1439. (g) Y.-H. Song, *Heterocycl. Commun.*, 2007, **13**, 33.
 19. J. Sandstorm, *Acta. Chem. Scand.*, 1961, **15**, 1295.
 20. N. S. A. M. Khalil, *Eur. J. Med. Chem.*, 2007, **42**, 1193.

Received on June 12, 2011.